These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
306 related articles for article (PubMed ID: 10203263)
41. Proceedings of the First Global Workshop on Breast Cancer: pathways to the evaluation and clinical development of novel agents for breast cancer. Albain KS; Carey L; Gradishar WJ; Gralow JR; Lipton A; Rugo H; Tripathy D; Peck S; Abair T; Pegram M Clin Breast Cancer; 2010 Dec; 10(6):421-39. PubMed ID: 21147685 [TBL] [Abstract][Full Text] [Related]
42. Evaluation of new drugs and combinations in gynecologic tumors and cancer cell lines with the ATP-cell viability assay. Untch M; Sevin BU Contrib Gynecol Obstet; 1994; 19():145-55. PubMed ID: 7995046 [No Abstract] [Full Text] [Related]
43. Principles of current cancer chemotherapy. Wiemann MC; Calabresi P Compr Ther; 1983 Mar; 9(3):46-52. PubMed ID: 6839689 [TBL] [Abstract][Full Text] [Related]
44. Chemotherapy: updates and new perspectives. Swain SM Oncologist; 2011; 16 Suppl 1():30-9. PubMed ID: 21278439 [TBL] [Abstract][Full Text] [Related]
45. Pharmacokinetics and pharmacodynamics of anticancer agents: contributions to the therapy of childhood cancer. Petros WP; Evans WE Pharmacotherapy; 1990; 10(5):313-25. PubMed ID: 2235668 [TBL] [Abstract][Full Text] [Related]
46. The relationship between high-dose treatment and combination chemotherapy: the concept of summation dose intensity. Frei E; Elias A; Wheeler C; Richardson P; Hryniuk W Clin Cancer Res; 1998 Sep; 4(9):2027-37. PubMed ID: 9748116 [TBL] [Abstract][Full Text] [Related]
47. The development of dose-dense adjuvant chemotherapy. Hudis C; Dang C Breast J; 2015; 21(1):42-51. PubMed ID: 25530009 [TBL] [Abstract][Full Text] [Related]
48. Mobilization of peripheral blood progenitor cells by hematopoietic growth factors. Chao NJ Can J Oncol; 1995 Dec; 5 Suppl 1():43-6. PubMed ID: 8853524 [TBL] [Abstract][Full Text] [Related]
49. Cancer chemotherapy. Secchi GC Ann Ital Med Int; 1990; 5(3 Pt 3):288-95. PubMed ID: 2081089 [TBL] [Abstract][Full Text] [Related]
50. The clinical application of chronobiology to oncology. Hrushesky WJ Am J Anat; 1983 Dec; 168(4):519-42. PubMed ID: 6198896 [TBL] [Abstract][Full Text] [Related]
51. New directions for breast cancer therapeutic research. Friedman MA Hematol Oncol Clin North Am; 1994 Feb; 8(1):113-9. PubMed ID: 8150774 [TBL] [Abstract][Full Text] [Related]
53. Cancer therapy with combinations of biological response modifiers and cytotoxics: an update. Borden EC; Creekmore SP Cancer Cells; 1990 Jul; 2(7):217-20. PubMed ID: 2204387 [TBL] [Abstract][Full Text] [Related]
54. [Significance of the cell cycle for the effect of antineoplastic chemotherapy]. Matthias M Acta Histochem Suppl; 1983; 27():95-104. PubMed ID: 6408710 [TBL] [Abstract][Full Text] [Related]
55. Some thoughts on experimental screening. Carter SK Biomedicine; 1975 Jan; 22(1):5-17. PubMed ID: 1101978 [TBL] [Abstract][Full Text] [Related]
56. Adjuvant chemotherapy for breast cancer. Schnipper LE; Come SE Compr Ther; 1980 Oct; 6(10):42-7. PubMed ID: 7449364 [No Abstract] [Full Text] [Related]
57. Clinical concepts derived from animal chemotherapy studies. Goldin A; Schabel FM Cancer Treat Rep; 1981; 65 Suppl 3():11-9. PubMed ID: 7049366 [TBL] [Abstract][Full Text] [Related]
58. Biology of residual breast cancer after therapy: a kinetic interpretation. Norton L Prog Clin Biol Res; 1990; 354A():109-32. PubMed ID: 2247484 [No Abstract] [Full Text] [Related]
59. Mechanisms of drug resistance in breast cancer. Dalton WS Semin Oncol; 1990 Aug; 17(4 Suppl 7):37-9. PubMed ID: 2200130 [TBL] [Abstract][Full Text] [Related]
60. Scientific basis and criticism of current therapy of acute leukemia. Stryckmans P; Delforge A; Bron D; Malarme M; Debusscher L; Suciu S; Ronge-Collard E Blood Cells; 1982; 8(3):603-22. PubMed ID: 6760936 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]